StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Fosamax by Quarter

Fosamax (alendronate, legacy pre-Organon spin-off) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)

Merck Fosamax: -16.0% in Q4 2018, down 6.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2018
-16.0%
Period ended Dec 31, 2018
Change on a year earlier
-6.0 pts
-10.0% in Q4 2017
History
5 quarters
Since Q4 2017
Sources
5
Documents cited below

Where the Q4 2018 figure comes from

“|| Fosamax | 55 | 59 | 45 | 50 | 209 | 61 | 66 | 53 | 62 | 241 | -18 | -16 | -13 | -15”

Source: Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗

Reported in Form 8-K Table 3 / 10-K / 10-Q MD&A.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFosamax (alendronate, legacy pre-Organon spin-off) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)Year on yearSource
Q4 2018Dec 31, 2018-16.0%-6.0 ptsForm 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2018Sep 30, 2018-14.0%–Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗
Q2 2018Jun 30, 2018-15.0%–Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗
Q1 2018Mar 31, 2018-17.0%–Form 8-K (a18-12417_1ex99d1.htm, filed 2018-05-01) ↗
Q4 2017Dec 31, 2017-10.0%–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Cite this data

StockData. (2026). Merck Fosamax (%), quarterly Q4 2017–Q4 2018 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-fosamax-ww-exfx-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.